U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22O8
Molecular Weight 414.4061
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PODOFILOX

SMILES

COc1cc(cc(c1OC)OC)[C@]2([H])c3cc4c(cc3[C@@]([H])([C@@]5([H])COC(=O)[C@@]52[H])O)OCO4

InChI

InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H22O8
Molecular Weight 414.4061
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603 http://products.sanofi.ca/en/condyline.pdf

Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095182
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CONDYLOX

Approved Use

Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.

Launch Date

6.6104643E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (79.2%)
Pain (79.2%)
Itching (83.3%)
Bleeding (45.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (49.4%)
Pain (54.3%)
Itching (59.3%)
Bleeding (29.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (52.3%)
Pain (55.8%)
Itching (60.5%)
Bleeding (32.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (83.2%)
Pain (49.6%)
Itching (52.9%)
Bleeding (28.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (81.9%)
Pain (50.4%)
Itching (52.8%)
Bleeding (26.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (71.4%)
Pain (71.4%)
Itching (57.1%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (mild, 32.2%)
Pain (mild, 23.7%)
Itching (mild, 32.2%)
Bleeding (mild, 19.2%)
Inflammation (moderate, 30.4%)
Pain (moderate, 20.4%)
Itching (moderate, 16%)
Bleeding (moderate, 3%)
Inflammation (severe, 9.3%)
Pain (severe, 11.5%)
Itching (severe, 7.8%)
Bleeding (severe, 0.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bleeding 45.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Inflammation 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Pain 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Itching 83.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
Bleeding 29.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Inflammation 49.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Pain 54.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Itching 59.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
Bleeding 32.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Inflammation 52.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Pain 55.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Itching 60.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
Bleeding 28.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Pain 49.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Itching 52.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Inflammation 83.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
Bleeding 26.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Pain 50.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Itching 52.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Inflammation 81.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
Itching 57.1%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Inflammation 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Pain 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
Bleeding mild, 19.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain mild, 23.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching moderate, 16%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain moderate, 20.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Bleeding moderate, 3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation moderate, 30.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Bleeding severe, 0.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Pain severe, 11.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Itching severe, 7.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Inflammation severe, 9.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
2001 Dec
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
2001 Dec
[Synthesis and activities of 4-deoxy-4 beta-arylmehtylene sulfonylamido-4'-demethylpodophyllotoxins].
2001 Feb
The treatment of anogenital warts at home.
2001 Feb 8-14
Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia.
2002
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
2002
Minimising the long-term adverse effects of childhood leukaemia therapy.
2002
Evaluation of Podophyllum peltatum accessions for podophyllotoxin production.
2002 Apr
Clinical inquiries. What is the most effective treatment for external genital warts?
2002 Apr
Facial molluscum: treatment with cryotherapy and podophyllotoxin.
2002 Apr
Antitumor and antioxidant activity of spin labeled derivatives of podophyllotoxin (GP-1) and congeners.
2002 Apr 5
Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak.
2002 Aug
Antioxidative activity of spin labeled derivatives of podophyllic acid hydrazide.
2002 Aug
[External anogenital condylomas].
2002 Aug-Sep
[Management of external genital warts by dermatologists: a French survey].
2002 Aug-Sep
[Incidence and management of condylomata acuminata by French general physicians].
2002 Aug-Sep
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
2002 Dec 15
Prodrugs of 4'-demethyl-4-deoxypodophyllotoxin: synthesis and evaluation of the antitumor activity.
2002 Dec 2
An epiisopicropodophyllin aza analogue via palladium-catalyzed pseudo-domino cyclization.
2002 Dec 27
Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.
2002 Jan-Feb
Unusual implantation site of a port-a-cath system via the right femoral vein.
2002 Jul
[Poisoning with a podophyllin-containing wart-treating tincture].
2002 Jul 12
Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells.
2002 Jul-Aug
Optimization of culture parameters for production of podophyllotoxin in suspension culture of Podophyllum hexandrum.
2002 Jul-Dec
Flow cytometric estimation on cytotoxic activity of leaf extracts from seashore plants in subtropical Japan: isolation, quantification and cytotoxic action of (-)-deoxypodophyllotoxin.
2002 Jun
Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells.
2002 Jun 14
A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
2002 Jun 25
Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana.
2002 Mar
Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
2002 Mar
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
2002 May 20
Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method.
2002 May 23
Effect of the DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast chromosomes.
2002 May 29
Hemi-synthesis and biological activity of new analogues of podophyllotoxin.
2002 Nov
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002 Oct
Experimental study of podophyllotoxin dipalmitoylphosphatidylcholine liposome for topical skin application.
2002 Oct
Biosynthesis of podophyllotoxin in Linum album cell cultures.
2002 Oct
Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain.
2002 Oct 1
Meiotic telomere clustering is inhibited by colchicine but does not require cytoplasmic microtubules.
2002 Oct 1
External genital warts: diagnosis, treatment, and prevention.
2002 Oct 15
Four lignans from Commiphora erlangeriana.
2002 Sep
[Changes in serum concentration of podophyllotoxin after its topical application with liposome on rat skin].
2002 Sep
Cytogenetic analysis of giant oocytes and zygotes to assess their relevance for the development of digynic triploidy.
2002 Sep
A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives.
2002 Sep 19
Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription.
2003 Apr 11
Naphthalene analogues of lignans.
2003 Feb 7
Synthesis and cytotoxicity of podophyllotoxin analogues modified in the A ring.
2003 Jan
Effect of major nutrients on podophyllotoxin production in Podophyllum hexandrum suspension cultures.
2003 Jan
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
2003 Jan
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
2003 Jan 13
[Bacteremia due to Capnocytophaga spp.: two cases].
2003 Mar
Patents

Sample Use Guides

Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:08:40 UTC 2021
Edited
by admin
on Fri Jun 25 21:08:40 UTC 2021
Record UNII
L36H50F353
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PODOFILOX
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
PODOPHYLLOTOXIN [EP MONOGRAPH]
Common Name English
NSC-24818
Code English
PODOFILOX [VANDF]
Common Name English
PODOPHYLLOTOXIN
MART.   MI   WHO-DD  
Common Name English
PODOFILOX [ORANGE BOOK]
Common Name English
PODOPHYLLOTOXIN [MI]
Common Name English
PODOPHYLLOTOXIN [WHO-DD]
Common Name English
PODOPHYLLOTOXIN [MART.]
Common Name English
CONDYLOX
Brand Name English
PODOFILOX [HSDB]
Common Name English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.ALPHA.))-
Common Name English
(5R,5AR,8AR,9R)-5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
Common Name English
PODOFILOX [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008732
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
NCI_THESAURUS C67421
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
WHO-ATC D06BB04
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
WHO-VATC QD06BB04
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
Code System Code Type Description
PUBCHEM
10607
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
HSDB
7238
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
EVMPD
SUB14925MIG
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
RXCUI
8463
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M8933
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL61
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
CAS
518-28-5
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
FDA UNII
L36H50F353
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
NCI_THESAURUS
C29368
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
WIKIPEDIA
PODOPHYLLOTOXIN
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
DRUG CENTRAL
3481
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
MESH
D011034
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
ECHA (EC/EINECS)
208-250-4
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
EPA CompTox
518-28-5
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
DRUG BANK
DB01179
Created by admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY